IAM
Iambic Therapeutics, Inc. (IAM)
Healthcare • NASDAQ • $16.98-28.69%
- Symbol
- IAM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $16.98
- Daily Change
- -28.69%
- Market Cap
- $1.13B
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $25.00
- 52W Low
- $16.15
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- N/A
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Company websiteResearch IAM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.